US 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study - Initial Formulation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00085852
Recruitment Status : Completed
First Posted : June 17, 2004
Last Update Posted : March 6, 2008
Information provided by:
Aeris Therapeutics

Brief Summary:
The purpose of this study is to determine whether the Aeris Bronchoscopic Lung Volume Reduction (BLVR) System is safe in patients with advanced emphysema.

Condition or disease Intervention/treatment Phase
Pulmonary Emphysema Biological: BLVR Phase 1

Detailed Description:

Patients with emphysema currently have limited treatment choices. Many patients are treated with steroids and inhaled medications, which often provide little or no benefit. Recently, lung volume reduction surgery has become an accepted therapy for emphysema. Lung volume reduction surgery involves the removal of a diseased portion of the lung, which enables the remaining, healthier portions of the lung to function better. This procedure, although effective, is complicated and risky.

Aeris Therapeutics has developed the Aeris Bronchoscopic Lung Volume Reduction System for treatment of patients with advanced emphysema. The Aeris BLVR System is designed to reduce lung volume without surgery. Patients are treated under anesthesia using a bronchoscope to direct treatment to the most damaged areas of the lung. The treatment is expected to reduce lung volume by shrinking the diseased areas of the lung. The purpose of the current study is to find out whether the Aeris BLVR System is safe in patients with advanced emphysema. The risks associated with the treatment are expected to be similar to those associated with general anesthesia and bronchoscopy.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study of the Aeris Bronchoscopic Lung Volume Reduction (BLVR) System in Patients With Advanced Heterogeneous Emphysema
Study Start Date : April 2005
Actual Primary Completion Date : October 2006
Actual Study Completion Date : June 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Emphysema

Arm Intervention/treatment
Experimental: Single
Treatment with BLVR
Biological: BLVR
10 mL Hydrogel

Primary Outcome Measures :
  1. SAEs - Safety [ Time Frame: 1 year post treatment ]

Secondary Outcome Measures :
  1. PFTs [ Time Frame: 12 weeks post treatment ]
  2. Dyspnea [ Time Frame: 12 weeks post treatment ]
  3. Exercise capacity [ Time Frame: 12 weeks post treatment ]
  4. QOL [ Time Frame: 12 weeks post treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Advanced emphysema
  • Limited exercise capacity and persistent symptoms despite medical therapy
  • Age between 18 and 75
  • No significant heart, kidney or liver disease
  • Willingness and ability to tolerate bronchoscopy
  • No prior Lung Volume Reduction Surgery or Lung Transplantation
  • Screening test results indicating that the procedure is appropriate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00085852

United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Caritas St Elizabeth's Medical Center
Boston, Massachusetts, United States, 02135
Sponsors and Collaborators
Aeris Therapeutics
Principal Investigator: John J. Reilly, MD Brigham and Women's Hospital

Responsible Party: Edward P Ingenito, MD, PhD, Medical Director & CSO, Aeris Therapeutics Inc Identifier: NCT00085852     History of Changes
Other Study ID Numbers: C04-001
IRB Protocol # 2003-P-002171
First Posted: June 17, 2004    Key Record Dates
Last Update Posted: March 6, 2008
Last Verified: February 2008

Keywords provided by Aeris Therapeutics:
chronic obstructive pulmonary disease
lung volume reduction

Additional relevant MeSH terms:
Pulmonary Emphysema
Pathologic Processes
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases